Poseida Therapeutics Inc. has received FDA clearance of its IND application for P-CD19CD20-ALLO1, an allogeneic dual chimeric antigen receptor (CAR) T-cell product candidate being developed for relapsed or refractory B-cell malignancies in partnership with F. Hoffmann-La Roche Ltd. The company is actively focused on opening clinical sites for a phase I study in adults with relapsed or refractory B-cell malignancies.
IPSirius SAS, an early stage French immuno-oncology firm, hopes to obtain a clinical trial authorization from the U.K.’s Medicines and Healthcare Regulatory Products Agency next year, to enable it to move its novel therapeutic cancer vaccine into a first-in-human trial in patients with non-small-cell lung cancer.
Researchers from Parthenon Therapeutics Inc. and affiliated organizations presented preclinical data for a novel antiepithelial discoidin domain-containing receptor 1 (DDR1) antibody, PRTH-101, being developed for the treatment of cancer.
Domain Therapeutics SA has nominated a novel drug candidate, DT-7012, an anti-CCR8 monoclonal antibody depleting tumor-infiltrating regulatory T cells (Tregs).
Coimmune Inc. has obtained a license to target delta-like ligand 3 (DLL3) with IL-18 armored chimeric antigen receptor (CAR) technology. The company exercised an option to obtain an exclusive license in the DLL3-targeted, allogeneic CAR-cytokine induced killer (CAR-CIK) cell therapy field to IL-18 armored CAR technology under an agreement with Memorial Sloan Kettering Cancer Center (MSK).
B cells that expressed a constellation of checkpoint inhibitors could be spurred into antitumor activity by deleting or blocking the checkpoint molecule T-cell immunoglobulin and mucin domain 1 (TIM-1). The findings, which were published online in Nature on June 21, 2023, suggest ways to bring B cells into the antitumor fight. More broadly, Lloyd Bod told BioWorld, his laboratory aims to “break the dogma that B cells only produce antibodies.”
Osteosarcomas (OS) are the most common malignant bone tumor. The disease originates within the fastest growing areas of the long bones of children and young adults, where the histologic hallmark of OS is malignant bone formation (osteoid). Improvements in treatments have proven difficult to date with metastatic OS remaining a bleak prognosis routinely leading to lung metastases to ultimately cause death.
Larkspur Biosciences Inc. recently published findings uncovering a role for B cells in antitumor immunity, and highlighting TIM-1 as a targetable checkpoint protein central to B-cell antitumor activity.
Researchers from Westlake Therapeutics (Hangzhou) Co. Ltd. have presented the discovery and preclinical evaluation of a novel erythrocyte-anti-PD-1 antibody conjugate, WTX-212, being developed for the treatment of cancer.
Back-to-back papers in the June 22, 2023, issue of Nature have identified separate molecular mechanisms underlying sex-specific cancer outcomes. Researchers from The University of Texas MD Anderson Cancer Center showed that increased expression of the epigenetic enzyme KDM5D, which is located on the Y chromosome, contributed to cancer progression in KRAS-mutated tumors. In the same issue of Nature, a team from Cedars-Sinai reported new insights into the consequences of losing the entire Y chromosome.
RSS
